europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

Europe’s Rare Disease SMEs raise their voice for success

25/04/2023

NEWS RELEASE

Brussels, 25 April 2023 - On February 28th 2023, Rare Disease Day, EuropaBio's Small and Medium-sized Enterprises (SME) Platform hosted a session on rare diseases and invited European SMEs to share their experiences and discuss the current regulatory and incentives framework ahead of the revision of the pharmaceutical legislation and the legislations on orphan and paediatric medicines. Participants discussed Research and Development, Regulation, and the European Market and investment environment.

 

Science, Research and Development

Each rare disease affects a small number of people, which brings significant challenges in clinical trial design and recruitment, alongside the limited knowledge of the overall clinical evidence and disease progression process.

Participants discussed the importance of data sharing and patient registries to fill information gaps and the European Medicines Agency's essential support in protocol assistance and scientific advice.

 

Regulatory frameworks

Smaller companies discussed the concept of unmet medical needs and why it must stay broader, allowing to guide investment in areas with fewer therapeutic options and where scientific developments are more promising. Participants discussed some of the challenges and considerations for market launch in Europe and how they can't do it in all 27 Member States. Challenges include the lack of rare disease patients in some countries, country-specific requirements (e.g., the need for pharmacovigilance departments) and the lack of specialized care centres able to administer complex new treatments.

 

Market and investment environment

As national healthcare structures evolve, new technologies are adopted, public awareness increases, and information is improved, more rare disease patients will be diagnosed, creating additional financial pressure in an already underfunded sector.

Smaller companies face a challenging financial environment and struggle to raise investment from public and private partners to finance their products' research and development. They must have a predictable legal framework to make informed long-term decisions and be able to raise external capital to address the EU's market fragmentation.

 

Please consult our event report for our session's conclusion and SME recommendations.

Rare diseases – SME BioForum report 2023


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
19/09/2022

Biotech SMEs are the heart of Europe’s healthcare ecosystem – hear their voice.


Read more
07/09/2022

Advanced therapy medicinal products: SMEs call for a better investment environment in Europe


Read more
23/05/2022

Big Changes Start Small


Read more

Important links

  • SwedenBIO joins EuropaBio: helping innovative companies succeed!
  • Ajinomoto Europe joins EuropaBio: unlocking the power of amino acids

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies